Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF11167 for negative symptoms in schizophrenia
NCT03793712Phase 2Terminated
- Sponsor
- Lundbeck
- Start
- Dec 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of Lu AF11167 in schizophrenia (3 arms), sponsored by Lundbeck. Primary endpoint: Brief Negative Symptom Scale Total Score at 12 weeks. Started Dec 2018; status: terminated.
02
Drugs
Lu AF11167
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03793712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793712.